Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acne Infection01:27

Acne Infection

94
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
94
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.2K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Staphylococcal Skin Infections01:29

Staphylococcal Skin Infections

143
Staphylococcus aureus is a Gram-positive coccus that resides harmlessly on the skin and mucous membranes of healthy individuals. When the skin barrier is breached, it can shift from a commensal to an opportunistic pathogen. This transition is facilitated by surface adhesins, such as clumping factor B and S. aureus surface protein G (SasG), which bind to structural proteins, including loricrin and cytokeratin, in the damaged epidermis. Protein A, another key factor, binds the Fc region of...
143
Hypersensitivities01:30

Hypersensitivities

7.3K
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
7.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A).

Cell death and differentiation·2007
Same author

Pharmacological inhibition of GSK-3 is not strictly correlated with a decrease in tyrosine phosphorylation of residues 216/279.

Journal of neuroscience research·2007
Same author

Type 2 diabetes mellitus: epidemiology, pathophysiology, unmet needs and therapeutical perspectives.

Diabetes & metabolism·2007
Same author

Density functional study of structural and electronic properties of small bimetallic silver-nickel clusters.

The journal of physical chemistry. A·2007
Same author

Increased lipopolysaccharide-induced tumour necrosis factor-alpha, interferon-gamma and interleukin-10 production in atopic dermatitis.

The British journal of dermatology·2007
Same author

Anaplasma phagocytophilum in dogs in Germany.

Zoonoses and public health·2007
Same journal

Detergent-Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans.

Allergy·2026
Same journal

Global Variation in Timing of Allergenic Food Introduction for Food Allergy Prevention: An International Survey of Healthcare Professionals.

Allergy·2026
Same journal

Deficiency of Mitochondrial Fatty Acid Enzyme, CPT1A, Underlies Airway Epithelial Barrier Dysfunction in Severe Asthma.

Allergy·2026
Same journal

Surgical Management of Non-Allergic Rhinitis-An EAACI Task Force Position Paper.

Allergy·2026
Same journal

Real-World Evaluation of AI-Assisted Readout of Skin Prick Automated Test Results.

Allergy·2026
Same journal

Serotonin Degradation and Lipid Metabolism Regulate Human Tc2 Cell Effector Functions.

Allergy·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K

Systemic therapy for atopic dermatitis.

D Simon1, T Bieber

  • 1Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Allergy
|December 21, 2013
PubMed
Summary
This summary is machine-generated.

Systemic therapy for severe atopic dermatitis (AD) is reserved for patients unresponsive to topical treatments. This review examines current systemic options for AD, highlighting the need for more controlled studies.

Keywords:
atopic dermatitisimmunosuppressioninflammation

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

6.6K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.3K

Related Experiment Videos

Last Updated: May 4, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.4K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

6.6K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.3K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a common inflammatory skin condition.
  • Severe AD cases often require systemic therapy when topical treatments fail.
  • Current systemic drugs modulate immune responses to reduce inflammation and symptoms like pruritus.

Purpose of the Study:

  • To review recent clinical trials and case reports on systemic therapy for pediatric and adult atopic dermatitis.
  • To draw conclusions for clinical practice regarding the use of systemic treatments for AD.
  • To assess the current landscape of systemic drug efficacy and availability for severe AD.

Main Methods:

  • Systematic review of published clinical trials and case reports on systemic AD therapy.
  • Analysis of drug selection criteria including disease severity, patient factors, and cost.
  • Evaluation of evidence for various systemic agents, with a focus on cyclosporine.

Main Results:

  • Controlled clinical studies on systemic AD therapies are limited, with cyclosporine being an approved option for severe cases.
  • Systemic drug selection is multifactorial, considering disease characteristics, patient profile, and practical aspects.
  • Antibiotic use for AD should be restricted to cases with clear infections due to resistance concerns.

Conclusions:

  • Systemic therapy is a crucial option for severe atopic dermatitis refractory to topical treatments.
  • Further controlled clinical studies are needed to establish the efficacy and safety of various systemic agents for AD.
  • Careful patient selection and consideration of drug availability and cost are essential for effective systemic AD management.